Nursing Homes and AsepticSure™

Posted in These Categories: News of Hospital Acquired Infections

AsepticSure™ treats C-difficile which is turning up more and more in nursing homes due to the close quarters, easy transference and age of patient.

People most vulnerable to a C difficile are those who:

Have been treated with broad-spectrum antibiotics. Have had to stay for a long time in a hospital or nursing home. Are over 65 years old. Have a serious underlying illness or condition. Have a weakened immune system. Have had numerous enemas or gut surgery.

C difficile is extremely contagious and is spread very easily. It can lead to symptoms such as diarrhea and fever and is usually caused by antibiotics.

Most people make a full recovery but in a minority of cases the infection can be fatal. In Britain the 75-84 year age group had the highest number of cases.

It is estimated that C difficile recurs after treatment in 20-30% of cases.

When a patient has the infection the advice is to stop taking the antibiotics which caused it if possible. This is aimed at allowing natural ‘good’ bacteria to re-grow in the gut and if the infection is mild to moderate this may be enough.

For those suffering a more severe infection however, it is necessary to take another antibiotic to kill off the C difficile. In rare and serious cases, surgery may be needed to repair damage to the intestines, especially if there are tears in the small intestine.

Contact: Medizone International, Inc. (OTCBB: MZEI)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Share and Enjoy: